Episodes
Ask host to enable sharing for playback control

Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks

7/21/2025
Guest: Parul Rai Cardiopulmonary complications are a leading cause of early mortality in adults with sickle cell disease, with evidence showing that cardiac injury may begin as early as childhood. However, despite the severity of these issues, there are currently no uniform guidelines for asymptomatic cardiac screening in this population. Join Dr. Parul Rai, a physician in the Department of Hematology at St. Jude’s Hospital in Memphis, Tennessee, to learn about current research, early detection strategies, and the need for more sensitive diagnostic markers to prevent severe cardiac outcomes in patients with sickle cell disease.

Duration:00:04:00

Ask host to enable sharing for playback control

Partnering for Better Hypertension Outcomes: How AMA and Azara Support Providers

7/16/2025
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jeff Brandes By embedding evidence-based metrics directly into existing workflows, the partnership between the American Medical Association (AMA) and Azara Healthcare supports providers in proactively managing hypertension. To learn more about how integrating the AMA MAP™ Hypertension Quality Improvement Program into Azara’s population health tools empowers clinicians to seamlessly deliver guideline-driven care, Dr. Charles Turck speaks with Mr. Jeff Brandes, President and CEO of Azara Healthcare.

Duration:00:07:29

Ask host to enable sharing for playback control

A Landmark Surgery That Saved Three Children With One Heart

7/2/2025
Guest: Andrew Goldstone, M.D., Ph.D. On this episode of Advances in Care, host Erin Welsh talks to Dr. Andrew Goldstone, pediatric cardiac surgeon at NewYork-Presbyterian and Columbia, about the groundbreaking heart transplant that saved the lives of three separate children. It was the first time doctors at NewYork-Presbyterian Morgan Stanley Children’s Hospital performed a split-root domino partial heart transplant. In this procedure, one child was transplanted with a new heart and their original heart was used to donate living pulmonary and aortic valves to two separate recipients in need. Dr. Goldstone, his colleague Dr. David Kalfa, and the rest of the team at NewYork-Presbyterian and Columbia had previous experience with a handful of domino partial heart transplants where one patient is transplanted with a new heart and another receives a valve from the explanted heart. Those experiences helped prepare for the split-root domino, which took nearly 24 hours of extremely coordinated care. In addition to their efforts to increase the number of domino heart transplants being done, physician-researchers at the institution are leading new studies that are also helping improve living valve procurement and storage, allowing more children to receive heart valves that will grow with them and require less surgeries. © 2025 …

Duration:00:22:00

Ask host to enable sharing for playback control

Scaling Success: Hypertension Control at MPCA with the AMA MAP™ Program

6/23/2025
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Faiyaz Syed MD, MPH The Michigan Primary Care Association (MPCA) recently partnered with the AMA to implement the AMA MAP™ Hypertension Quality Improvement Program at two pilot health centers. After this collaboration resulted in a 6 percent improvement in hypertension control, it’s now expanding to all other MPCA health centers and could even focus on other conditions like diabetes. Joining Dr. Mary Katherine Cheeley to share his experience with the AMA MAP™ program is Dr. Faiyaz Syed, Chief Medical Officer for the MPCA.

Duration:00:11:27

Ask host to enable sharing for playback control

The Latest in Stroke Risk Reduction Strategies: Are Your Patients Protected?

6/11/2025
Host: Alejandro A. Rabinstein, MD, FAHA Guest: Richard E. Pratley, MD Guest: Jay H. Shubrook, DO, FACOFP, FAAFP Listen to expert faculty discuss the role of GLP-1RAs in reducing stroke risk for patients with type 2 diabetes in this on-demand webcast with accompanying slides

Duration:00:52:09

Ask host to enable sharing for playback control

Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF

6/10/2025
Host: Riccardo Maria Inciardi, MD, PhD Listen to Dr. Riccardo Inciardi’s summary from the ESC Preventive Cardiology 2025 meeting, where he highlights new therapies reshaping the management of cardio-kidney-metabolic (CKM) syndrome and heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Watch as he breaks down the latest clinical trial data showing that SGLT2 inhibitors, GLP-1 receptor agonists, and the nonsteroidal MRA finerenone can meaningfully reduce hospitalizations, kidney disease progression, and cardiovascular mortality. A real-life patient case illustrates how combining these therapies—under the care of a multidisciplinary team—can transform outcomes.

Duration:00:13:29

Ask host to enable sharing for playback control

Bridging ASCVD Care Between Academic and Rural Settings

6/10/2025
Host: Rishi Wadhera, MD, MPP, Mphil Guest: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Duration:00:05:00

Ask host to enable sharing for playback control

Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment

6/10/2025
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Guest: Rishi Wadhera, MD, MPP, Mphil Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Duration:00:05:27

Ask host to enable sharing for playback control

Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences

6/10/2025
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Guest: Rishi Wadhera, MD, MPP, Mphil Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Duration:00:05:14

Ask host to enable sharing for playback control

Target in Sight: Escalating Therapy to Reach LDL-C Goals

6/10/2025
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Guest: Rishi Wadhera, MD, MPP, Mphil Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Duration:00:05:29

Ask host to enable sharing for playback control

Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up

6/10/2025
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Guest: Rishi Wadhera, MD, MPP, Mphil Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Duration:00:04:59

Ask host to enable sharing for playback control

Statins and Safety: What the Data Say About Dementia, Cancer, and More

6/10/2025
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Guest: Rishi Wadhera, MD, MPP, Mphil Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Duration:00:07:14

Ask host to enable sharing for playback control

When and Why to Use CAC Scoring

6/10/2025
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Guest: Rishi Wadhera, MD, MPP, Mphil Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Duration:00:04:30

Ask host to enable sharing for playback control

Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy

6/10/2025
Host: Rishi Wadhera, MD, MPP, Mphil Guest: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Duration:00:04:45

Ask host to enable sharing for playback control

The Dose Matters: Optimizing Statin Intensity in ASCVD Management

6/10/2025
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Guest: Rishi Wadhera, MD, MPP, Mphil Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Duration:00:02:45

Ask host to enable sharing for playback control

Where Does This Patient Land? Making Sense of Risk and LDL-C Goals

6/10/2025
Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Guest: Rishi Wadhera, MD, MPP, Mphil Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Duration:00:07:13

Ask host to enable sharing for playback control

Skin Disease and Cardiovascular Risk: Uncovering a Critical Clinical Connection

6/10/2025
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Joel M. Gelfand, MD, MSCE, FAAD Guest: Michael S. Garshick, MD Inflammatory skin diseases like psoriasis don’t just affect the skin—they can often reflect broader cardiovascular risks. Given the overlap between dermatology and cardiology, knowing how to spot warning signs early and what steps to take during routine visits is key to comprehensive care. Joining Dr. Mary Cheeley to discuss the connection between the skin and the heart are Drs. Joel Gelfand and Michael Garshick. Dr. Gelfand is a dermatologist at the University of Pennsylvania and the Director of the Psoriasis and Phototherapy Treatment Center and the Center for Clinical Sciences in Dermatology. Dr. Garshick is a cardiologist and the Director of the Cardio-Rheumatology Program at NYU Langone Health, as well as an Assistant Professor of Medicine and Dermatology at NYU Grossman School of Medicine.

Duration:00:11:59

Ask host to enable sharing for playback control

Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy

6/6/2025
Guest: prof. Hiddo Heerspink Guest: Jennifer B. Green, MD Can combining a nonsteroidal MRA and an SGLT2 inhibitor unlock new clinical potential for patients with type 2 diabetes and chronic kidney disease (CKD)? In this expert discussion, Dr. Jennifer Green and Dr. Hiddo Heerspink review the latest findings from the CONFIDENCE trial, which demonstrated a significant additive reduction in albuminuria—an important surrogate marker for kidney and cardiovascular risk—when finerenone and empagliflozin are used together. They explore the clinical rationale behind combination therapy, address persistent challenges in CKD detection, and consider the practical implications for implementing these therapies in high-risk populations.

Duration:00:15:43

Ask host to enable sharing for playback control

Shifting Treatment Paradigm in HFmrEF/HFpEF: Steroidal and Nonsteroidal MRAs

5/30/2025
Guest: Faiez Zannad, MD, PhD Guest: John McMurray, MD Join Drs. John McMurray and Faiez Zannad as they explore the evolving role of MRAs in heart failure management. From RALES and TOPCAT to the recent FINEARTS-HF trial, they highlight key findings that shape how steroidal and nonsteroidal MRAs are used in clinical practice. Discover how the nonsteroidal MRA finerenone is expanding treatment options for patients with HFmrEF and HFpEF.

Duration:00:16:29

Ask host to enable sharing for playback control

Remnant Cholesterol: The Missing Link in ASCVD risk

5/30/2025
Guest: Børge G. Nordestgaard, MD, DMSc Guest: Kausik Ray, MBChB, MD, MPhil There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

Duration:00:03:00